Statins do not increase breast cancer risk in postmenopausal women
1. Statin use did not increase the risk of developing breast cancer among postmenopausal women. Evidence Rating Level: 2 (Good) ...
Tag: postmenopausal
2 Minute Medicine Rewind April 6, 2026
Drying Very Preterm Infants Before Plastic Wrapping at Birth: A Randomized Clinical Trial 1. Drying before plastic wrapping did not ...
Self-administered hypnosis may improve hot flashes among postmenopausal women
1. Six weeks of self-administered hypnosis reduced hot flash scores and daily interference from hot flashes compared with sham hypnosis ...
2 Minute Medicine Rewind November 17, 2025
Vernakalant versus procainamide for rapid cardioversion of patients with acute atrial fibrillation (RAFF4): randomised clinical trial 1. Vernakalant was superior ...
#VisualAbstract: Infrequent Zoledronate over 10 years Prevents Frcatures in Early Postmenopausal Women
Click here to read this study in NEJM. ©2024 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced ...
The Scan by 2 Minute Medicine®: Vampire Facials: HIV in Pursuit of Beauty, Fentanyl Awareness Day, Marijuana Reclassification: Cannabis Restrictions to Ease?, Menopause Meds: A Safe Passage
The Scan by 2 Minute Medicine® is a pop-culture medical newsletter and exclusive benefit for 2 Minute Medicine Plus subscribers. ...
Higher cardiorespiratory fitness may be protective against breast cancer in postmenopausal women
1. In this prospective cohort study, higher cardiorespiratory fitness (CRF) was associated with a substantially lower risk of breast cancer ...
Wellness Check: Exercise
Higher cardiorespiratory fitness may be protective against breast cancer in postmenopausal women 1. In this prospective cohort study, higher cardiorespiratory ...
Fezolinetant significantly reduces vasomotor symptoms in post-menopausal women
1. Fezolinetant 30 mg and 45 mg significantly reduced the frequency and severity of vasomotor symptoms compared to placebo. 2. ...
Bisphosphonates, denosumab, abaloparatide, teriparatide, and romosozumab reduce postmenopausal fracture risk
1. Bisphosphonates, denosumab, abaloparatide, teriparatide, and romosozumab use are associated with reduced clinical fractures in postmenopausal patients with osteoporosis. 2. ...
